WO2023077678A1 - 靶向srsf6蛋白的小分子化合物及其制备方法和用途 - Google Patents

靶向srsf6蛋白的小分子化合物及其制备方法和用途 Download PDF

Info

Publication number
WO2023077678A1
WO2023077678A1 PCT/CN2022/072519 CN2022072519W WO2023077678A1 WO 2023077678 A1 WO2023077678 A1 WO 2023077678A1 CN 2022072519 W CN2022072519 W CN 2022072519W WO 2023077678 A1 WO2023077678 A1 WO 2023077678A1
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
compound
unsubstituted
benzyl
reaction
Prior art date
Application number
PCT/CN2022/072519
Other languages
English (en)
French (fr)
Inventor
余文颖
来茂德
王茼
李聪
张红河
李志裕
Original Assignee
中国药科大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中国药科大学 filed Critical 中国药科大学
Publication of WO2023077678A1 publication Critical patent/WO2023077678A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the invention relates to the fields of medicinal chemistry and pharmacotherapeutics, in particular to a small molecular compound targeting SRSF6 protein, its preparation method and application.
  • SR serpin/arginine-rich protein
  • RNA recognition motif located at the N-terminus.
  • SR protein is determined by the specific binding of pre-RNA by the RRM domain
  • Dysregulation of SR protein expression can lead to abnormal splicing processes, which in turn promote the occurrence of malignant tumors.
  • SRSF6 serine/arginine-rich splicing factor 6
  • SRSF6 can bind to the motif of exon 23 (exon23) of cell adhesion factor ZO-1, activate the splicing of ZO-1exon23, lead to the occurrence of abnormal alternative splicing, and then promote the occurrence and development of colorectal cancer.
  • Colorectal cancer is a common malignant tumor of the digestive tract formed on the inner wall of the colon or rectum. It is one of the malignant tumors that pose a great threat to human survival and health in the world today. the third. With the changes in residents' lifestyle and dietary structure, the incidence of colorectal cancer in my country is on the rise, ranking second among new cancers in my country. Colorectal cancer has complex etiology and can occur anywhere in the colon or rectum.
  • Indacaterol is a drug for adults with chronic obstructive pulmonary disease (COPD), and studies have shown that it can be used for the treatment of tumors, especially colorectal tumors; it regulates alternative splicing in cells, thereby To achieve the effect of inhibiting cell proliferation, migration and invasion.
  • COPD chronic obstructive pulmonary disease
  • the present invention provides a small molecular compound targeting SRSF6 protein and its preparation method and application.
  • the molecule can selectively inhibit abnormal cells with high expression of SRSF6, thereby reducing the occurrence of abnormal alternative splicing events, inhibiting the occurrence and development of tumors, especially colorectal tumors, and can be used as a candidate new drug for anti-colorectal cancer.
  • R 1 is selected from substituted or unsubstituted C 1 -C 3 linear alkyl, substituted or unsubstituted C 1 -C 3 alkenyl, substituted or unsubstituted C 6 -C 10 aryl, substituted or unsubstituted C 6 -C 10 aralkyl, C 6 -C 10 haloaralkyl or C 6 -C 10 heteroaryl ring group, wherein the heteroatoms of the heteroaryl are each independently selected from N, O, S;
  • R 2 is selected from C 1 -C 3 alkoxy, substituted amino, C 1 -C 8 aliphatic amino, saturated or unsaturated substituted or unsubstituted C 6 -C 10 aryl, substituted or unsubstituted C 6 -C 10 heteroaryl group, halogenated aromatic carbocyclic amino group or substituted or unsubstituted 5-7 membered heterocyclic group, wherein, the heteroatoms in the heteroaryl group or heterocyclic group are independently selected from N, O, S, halogenated halogen atoms refer to fluorine, chlorine, bromine or iodine; the substituted amino groups are respectively substituted by the following 1-3 substituents: C 1 -C 4 alkyl, 5,6-diethylindane substituted or unsubstituted phenyl, indanyl, indolyl, methylsulfonyl substituted piperidinyl, benzothiazolyl, benzimidazolyl;
  • X is selected from hydroxyl or halogen selected from fluorine, chlorine, bromine and iodine;
  • the chiral center* is in the S or R configuration.
  • R is selected from methyl, allyl, substituted or unsubstituted benzyl, substituted or unsubstituted pyridyl or triazole; the substituted or unsubstituted benzyl is represented by the following 1-3 groups Group independent substitution: halogen or C 1 -C 3 alkyl;
  • R is selected from R selected from methoxy, 5,6-diethyl-2,3-dihydro-1H-inden-2-amino, 2-aminoindanyl, anilino, bromoanilino, Heteroarylamino, C 1 -C 4 aliphatic amino, morpholinyl, piperidinyl, pyrrolyl, substituted or unsubstituted piperazinyl, substituted or unsubstituted homopiperazinyl, indolyl, 2, 3-dihydroindenyl, wherein, substituted or unsubstituted piperazinyl or substituted or unsubstituted homopiperazinyl is substituted by the following 1-3 independent substituents: C 1 -C 4 alkyl, substituted Or unsubstituted phenyl or substituted or unsubstituted benzyl, wherein the phenyl or benzyl is substituted by the following substituent groups: halogen or C
  • R is selected from benzyl, 3-substituted benzyl, 4-substituted benzyl or multi-substituted benzyl, and the substituent of said benzyl is methyl or halogen;
  • R2 is selected from 5,6-diethyl-2,3-dihydro-1H-indene-2-amino, N-benzopiperazinyl, N-benzohomopiperazinyl, bromoanilino, 2 , 3-dihydroindolyl or 2,3-dihydroindenyl;
  • the N-benzopiperazinyl group is selected from: benzyl substituted piperazinyl, methylbenzyl substituted piperazinyl or benzyl bromide Substituted piperazinyl;
  • N-benzo-substituted homopiperazinyl is selected from the group consisting of benzyl-substituted homopiperazinyl, methylbenzyl-substituted homopiperazinyl or benzyl bromide-substituted homopiperazinyl.
  • the multi-substituted benzyl is 3,5-halogenated benzyl, 3,4-halogenated benzyl or perhalogenated benzyl.
  • said R is selected from benzyl, 4-methylbenzyl, 3-fluorobenzyl, 4-fluorobenzyl, 3,5-difluorobenzyl, 3,4-difluorobenzyl, per Fluorobenzyl;
  • R is selected from 5,6-diethyl-2,3-dihydro-1H-indene-2-amino, 2-bromoanilino, 2,3-dihydroindolyl, 2,3-dihydro Indenyl, benzyl-substituted piperazinyl, 4-methylbenzyl-substituted piperazinyl, 4-bromobenzyl-substituted piperazinyl, benzyl-substituted homopiperazinyl, 4-methylbenzyl-substituted homopiperazinyl .
  • the compound is preferably selected from the following compounds:
  • the second aspect of the present invention provides the preparation method of the above-mentioned compound, comprising the following steps:
  • 5-acetyl-2,8-dihydroxyquinoline is reacted with R 1 X and then brominated to obtain compound II.
  • the brominating agent selected for bromination can be selected from bromine water, N-bromosuccinimide or tetrabutyl Ammonium tribromide; compound II is stereoselectively reduced to compound III by (R)/(S)-2-methyl-CBS-oxazolidine complex borane, and compound III has an intramolecular ring under alkaline conditions combined, and then react with the nucleophile R 2 H to obtain the target compound I, the synthetic route is as follows:
  • the solvent is selected from anhydrous acetonitrile, anhydrous dichloromethane, chloroform, anhydrous tetrahydrofuran, anhydrous N,N'-dimethylformamide, dimethyl sulfoxide One or more of them; according to their chiral requirements, select (R) or (S)-CBS chiral catalysts respectively, and carry out asymmetric reduction with borane; the reaction temperature is -20°C to 25°C.
  • the solvent is selected from one of acetonitrile, dichloromethane, chloroform, acetone, tetrahydrofuran, methanol, N,N-dimethylformamide, dimethyl sulfoxide or dioxane or more;
  • the base is selected from potassium carbonate, sodium carbonate, sodium bicarbonate, sodium hydroxide, potassium hydroxide or triethylamine; the reaction temperature is 25 ° C to reflux;
  • the solvent is selected from acetonitrile, N,N-dimethylformamide, dimethyl sulfoxide, n-butanol or diglyme; the reaction temperature is 60°C to 150°C ;
  • the solvent is selected from one or more of acetonitrile, dichloromethane, chloroform or tetrahydrofuran, reacts with a halogenating reagent under the protection of an inert gas, and the reaction temperature is from -20°C to 0°C.
  • the solvent is selected from anhydrous tetrahydrofuran
  • the catalyst is selected from (R)-2-methyl-CBS-oxazolidine or (S) -2-Methyl-CBS-oxazoboridine, the reaction temperature is -20°C to 0°C;
  • the solvent is acetone
  • the base is potassium carbonate or triethylamine
  • the reaction temperature is 55°C to 65°C.
  • the solvent is n-butanol, and the reaction temperature is 110°C to 120°C.
  • the solvent is selected as dichloromethane, and the reaction is carried out under the protection of nitrogen, and the reaction temperature is -20°C to 0°C.
  • the third aspect of the present invention provides the application of the above compounds in the preparation of medicines for treating diseases related to malignant tumors.
  • the diseases related to malignant tumors are all kinds of tumors mediated by overexpression of SRSF6 protein, including colorectal tumors (colorectal tumors mediated by overexpression of SRSF6 protein).
  • indacaterol and its intermediates as positive controls, through in vitro cell experiments, it has been proved that the compounds of the present invention have significant inhibitory effects on colorectal cancer cell lines such as RKO, HT-29, and SW620. effect.
  • the compound of the present invention is used for targeted treatment of colorectal tumors and other tumors with high expression of SRSF6, and provides potential drug molecules for chemotherapy of colorectal cancer.
  • Fig. 1 is the verification of the binding effect of the representative compound I 1 of the present invention and the SRSF6 protein fragment.
  • compound II 1 (500mg, 1.27mmol) was added to a 100mL double-necked reaction flask, and anhydrous THF (15mL) and a catalytic amount of (S)-2-methyl-CBS-oxazoboridine were added (1M, 128 ⁇ L, 0.13mmol), placed in a cold trap at -10°C and stirred thoroughly. After 10 minutes, measure borane-tetrahydrofuran complex (1M, 1.54mL, 1.54mmol), slowly drop into the reaction system within half an hour, continue to stir at this temperature for 15min, TLC monitors the completion of the reaction, and methanol (5mL) Quenches the reaction.
  • compound II 1 (500mg, 1.27mmol) was added to a 100mL double-neck reaction flask, anhydrous THF (15mL) and a catalytic amount of (R)-2-methyl-CBS-oxazoboridine were added (1M, 128 ⁇ L, 0.13mmol), placed in a cold trap at -10°C and stirred thoroughly. After 10 minutes, measure borane-tetrahydrofuran complex (1M, 1.54mL, 1.54mmol), slowly drop into the reaction system within half an hour, continue to stir at this temperature for 15min, TLC monitors the completion of the reaction, and methanol (5mL) Quenches the reaction.
  • intermediate IV 2 was synthesized.
  • intermediate IV 2 300mg, 0.96mmol
  • 5,6 -Diethyl-2,3-dihydro-1H-indene-2-amine 200mg, 1.06mmol
  • the intermediate IV 1 (200 mg) was reacted with anhydrous methanol (2 mL), and purified by silica gel column chromatography to obtain 128 mg of the target product I 3 with a yield of 58.03%.
  • the target product I 9 can be obtained by replacing 4-fluorobenzyl bromide in Example 1 with 3,5-difluorobenzyl bromide, referring to the method and reaction conditions in Example 1.
  • step 1.4 in Example 1 the indacaterol intermediate 5-(2R)-2-oxiranyl-8-benzyloxy-2(1H)-quinolinone (200mg, 0.68mmol ) and 1-butylpiperazine (116mg, 0.82mmol), and purified by silica gel column chromatography, 82mg of the target product was obtained with a yield of 27.61%.
  • step 1.4 in Example 1 the indacaterol intermediate 5-(2R)-2-oxiranyl-8-benzyloxy-2(1H)-quinolinone (200mg, 0.68mmol ) and 1-benzylpiperazine (145mg, 0.82mmol) were reacted and purified by silica gel column chromatography to obtain 105mg of the target product with a yield of 32.79%.
  • step 1.4 in Example 1 the indacaterol intermediate 5-(2R)-2-oxiranyl-8-benzyloxy-2(1H)-quinolinone (200mg, 0.68mmol ) reacted with 1-(4-methylbenzyl)piperazine (156mg, 0.82mmol), and purified by silica gel column chromatography to obtain 125mg of the target product with a yield of 37.91%.
  • step 1.4 in Example 1 the indacaterol intermediate 5-(2R)-2-oxiranyl-8-benzyloxy-2(1H)-quinolinone (200mg, 0.68mmol ) reacted with 1-(4-bromobenzyl)piperazine (209mg, 0.82mmol), and purified by silica gel column chromatography to obtain 133mg of the target product with a yield of 35.56%
  • step 1.4 in Example 1 the indacaterol intermediate 5-(2R)-2-oxiranyl-8-benzyloxy-2(1H)-quinolinone (200mg, 0.68mmol ) reacted with 1-(4-fluorophenyl)piperazine (148mg, 0.82mmol), and purified by silica gel column chromatography to obtain 221mg of the target product with a yield of 68.45%.
  • step 1.4 in Example 1 the indacaterol intermediate 5-(2R)-2-oxiranyl-8-benzyloxy-2(1H)-quinolinone (200mg, 0.68mmol ) and 1-benzylhomopiperazine (130mg, 0.82mmol) were reacted and purified by silica gel column chromatography to obtain 101mg of the target product with a yield of 30.63%.
  • step 1.4 in Example 1 the indacaterol intermediate 5-(2R)-2-oxiranyl-8-benzyloxy-2(1H)-quinolinone (200mg, 0.68mmol ) and 1-(4-methylbenzyl)homopiperazine (167mg, 0.82mmol) were reacted and purified by silica gel column chromatography to obtain 98mg of the target product with a yield of 28.88%.
  • step 1.4 in Example 1 the indacaterol intermediate 5-(2R)-2-oxiranyl-8-benzyloxy-2(1H)-quinolinone (200mg, 0.68mmol ) reacted with morpholine (72mg, 0.82mmol), and purified by silica gel column chromatography to obtain 63mg of the target product with a yield of 24.29%.
  • step 1.4 in Example 1 the indacaterol intermediate 5-(2R)-2-oxiranyl-8-benzyloxy-2(1H)-quinolinone (200mg, 0.68mmol ) and piperidine (70mg, 0.82mmol) were reacted and purified by silica gel column chromatography to obtain 87mg of the target product with a yield of 33.71%.
  • step 1.4 in Example 1 the indacaterol intermediate 5-(2R)-2-oxiranyl-8-benzyloxy-2(1H)-quinolinone (200mg, 0.68mmol ) reacted with tetrahydropyrrole (58mg, 0.82mmol), and purified by silica gel column chromatography to obtain 85mg of the target product with a yield of 34.21%.
  • step 1.4 in Example 1 the indacaterol intermediate 5-(2R)-2-oxiranyl-8-benzyloxy-2(1H)-quinolinone (200mg, 0.68mmol ) reacted with aniline (76mg, 0.82mmol), and purified by silica gel column chromatography to obtain 60mg of the target product with a yield of 22.77%.
  • step 1.4 in Example 1 the indacaterol intermediate 5-(2R)-2-oxiranyl-8-benzyloxy-2(1H)-quinolinone (200mg, 0.68mmol ) reacted with 2-bromoaniline (141mg, 0.82mmol), and purified by silica gel column chromatography to obtain 85mg of the target product with a yield of 26.79%.
  • step 1.4 in Example 1 the indacaterol intermediate 5-(2R)-2-oxiranyl-8-benzyloxy-2(1H)-quinolinone (200mg, 0.68mmol ) reacted with isobutylamine (123mg, 0.82mmol), and purified by silica gel column chromatography to obtain 73mg of the target product with a yield of 29.22%.
  • step 1.4 in Example 1 the indacaterol intermediate 5-(2R)-2-oxiranyl-8-benzyloxy-2(1H)-quinolinone (200mg, 0.68mmol ) reacted with (S)-2,3-dihydro-1H-indan-1-amine (109mg, 0.82mmol), and purified by silica gel column chromatography to obtain 112mg of the target product with a yield of 38.51%.
  • step 1.4 in Example 1 the indacaterol intermediate 5-(2R)-2-oxiranyl-8-benzyloxy-2(1H)-quinolinone (200mg, 0.68mmol ) reacted with indoline (98mg, 0.82mmol), and purified by silica gel column chromatography to obtain 103mg of the target product with a yield of 36.62%.
  • step 1.4 in Example 1 the indacaterol intermediate 5-(2R)-2-oxiranyl-8-benzyloxy-2(1H)-quinolinone (200mg, 0.68mmol ) and 1-methylsulfonyl-4-aminopiperidine (146mg, 0.82mmol) were reacted and purified by silica gel column chromatography to obtain 52mg of the target product with a yield of 16.17%.
  • step 1.4 in Example 1 the indacaterol intermediate 5-(2R)-2-oxiranyl-8-benzyloxy-2(1H)-quinolinone (200mg, 0.68mmol ) and 1,3-benzothiazol-5-amine (123mg, 0.82mmol) were reacted and purified by silica gel column chromatography to obtain 84mg of the target product with a yield of 27.78%.
  • step 1.4 in Example 1 the indacaterol intermediate 5-(2R)-2-oxiranyl-8-benzyloxy-2(1H)-quinolinone (200mg, 0.68mmol ) and 2-aminobenzimidazole (109mg, 0.82mmol), and purified by silica gel column chromatography, 68mg of the target product was obtained with a yield of 23.38%.
  • indacaterol as a positive control, a concentration gradient of 10, 20, 30, and 40 ⁇ M was prepared, and its IC 50 for SW620 was fixed between 20-25 ⁇ M.
  • Compound I was prepared with the same concentration gradient for primary screening.
  • Compounds with lower IC 50 than indacaterol were subjected to secondary screening.
  • the concentration gradients of the compounds in the secondary screening were 1, 2, 4, and 8 ⁇ M.
  • Cell survival rate [(reading of experimental group-reading of blank group)/(reading of control group-reading of blank group)] ⁇ 100%.
  • indacaterol As a positive control, its IC 50 for RKO and HT29 was fixed at 10-15 ⁇ M, and other processes were the same as for SW620 cell line.
  • indacaterol As a positive control, its IC 50 for RKO and HT29 was fixed at 10-15 ⁇ M, and other processes were the same as for SW620 cell line.
  • SRSF protein plays an important role in gene expression regulation processes such as constitutive splicing of pre-mRNA, alternative splicing, mRNA export from the nucleus, and translation.
  • SRSF proteins are divided into two groups according to the number of RRM domains, among which SRSF6 has two domains, RRM1 and RRM2.
  • the RRM1 domain contains the conserved sequences of RNP-1 and RNP-2, which can bind to related RNAs; while the RRM2 domain contains the evolutionarily conserved SWQDLKD heptapeptide sequence.
  • the RRM1 and RRM2 domains play an irreplaceable role.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明公开了一种靶向SRSF6蛋白的小分子化合物及其制备方法和用途。化合物如式(I)所示。分子能够选择性抑制SRSF6高表达的异常细胞，从而减少异常可变剪接事件的发生，抑制肿瘤的发生与发展，特别是结直肠肿瘤，可作为抗结直肠癌的候选新药。

Description

靶向SRSF6蛋白的小分子化合物及其制备方法和用途 技术领域
本发明涉及药物化学和药物治疗学领域，具体涉及一种靶向SRSF6蛋白的小分子化合物及其制备方法和用途。
背景技术
研究表明，异常的可变剪接(AS)在肿瘤的发生与发展中普遍存在，大部分肿瘤相关基因由于异常剪接而产生异常的生理学功能。SR(serine/arginine-rich)蛋白是一类富含丝氨酸/精氨酸的剪接因子，其蛋白家族共存在12个SRSF成员，它们共同的结构包括位于N末端的RNA识别结构域(RNA recognition motif，RRM结构域)和位于C末端含有高度磷酸化的丝氨酸/精氨酸的结构域(arginine/serine-rich domain，RS结构域),SR蛋白通过RRM结构域特异性地结合pre-RNA来确定剪接的部位；RS结构域则募集其他剪接因子参与RNA的剪接。SR蛋白的表达失调，会导致各种剪接过程出现异常，进而促进恶性肿瘤的发生。SRSF6(serine/arginine-rich splicing factor 6)蛋白是SR蛋白家族的成员之一，研究表明其在结直肠癌、肺癌等癌症中表达上调。SRSF6可与细胞黏附因子ZO-1的外显子23(exon23)的基序结合，激活了ZO-1exon23的剪接，导致了异常可变剪接的发生，进而促进了结直肠癌的发生与发展。
结直肠癌(Colorectal cancer，CRC)是由结肠或直肠内壁上形成的常见消化道恶性肿瘤，是当今世界对人类生存和健康构成极大威胁的恶性肿瘤之一，列西方发达国家癌症死亡谱的第三位。随着居民生活方式和饮食结构的改变，结直肠癌在我国的发病率呈明显上升趋势,已位列我国新发癌症的第二位。结直肠癌病因复杂，可以发生在结肠或直肠的任何部位。茚达特罗是用于成人慢性阻塞性肺疾病(COPD)患者的药物，而有研究表明，其可用于肿瘤的治疗，特别是结直肠肿瘤；它是通过调控细胞中的可变剪接，从而达到抑制细胞增殖、迁移、侵袭的效果。
发明内容
发明目的：本发明提供靶向SRSF6蛋白的小分子化合物及其制备方法和用途。分子能够选择性抑制SRSF6高表达的异常细胞，从而减少异常可变剪接事件的发生，抑制肿瘤的发生与发展，特别是结直肠肿瘤，可作为抗结直肠癌的候选新药。
技术方案：本发明提供了如通式如式(I)所示的化合物：
Figure PCTCN2022072519-appb-000001
其中：
R 1选自取代或者非取代的C 1-C 3直链烷基、取代或者非取代的C 1-C 3烯基、取代或者非取代的C 6-C 10芳基、取代或者非取代的C 6-C 10芳烷基、C 6-C 10卤代芳烷基或C 6-C 10杂芳环基，其中，杂芳基的杂原子各自独立地选自N、O、S；
R 2选自C 1-C 3烷氧基、取代氨基、C 1-C 8脂肪胺基、饱和或不饱和的取代或者非取代的C 6-C 10芳基、取代或者非取代的C 6-C 10杂芳基、卤代芳香族的碳环胺基或取代或者非取代的5-7元杂环基，其中，杂芳基或者杂环基中的杂原子各自独立地选自N、O、S， 卤代的卤原子指氟、氯、溴或者碘；所述取代氨基被以下1-3个取代基分别取代：C 1-C 4烷基、5,6-二乙基茚满基、取代或者非取代苯基、茚满基、吲哚基、甲磺酰基取代的哌啶基、苯并噻唑基、苯并咪唑基；
X选自羟基或者卤素，所述卤素选自氟、氯、溴和碘；
手性中心*为S构型或R构型。
优选地，R 1选自甲基、烯丙基、取代或者非取代的苄基、取代或者非取代的吡啶基或者三氮唑；所述取代或者非取代的苄基被以下1-3个基团独立取代：卤素或者C 1-C 3烷基；
R 2选自R 2选自甲氧基、5,6-二乙基-2,3-二氢-1H-茚-2-胺基、2-氨基茚满基、苯胺基、溴苯胺基、杂芳胺基、C 1-C 4脂肪胺基、吗啉基、哌啶基、吡咯基、取代或者非取代的哌嗪基、取代或者非取代的高哌嗪基、吲哚基、2,3-二氢茚基，其中，取代或者非取代的哌嗪基或者取代或者非取代的高哌嗪基被下列的1-3个独立的取代基所取代：C 1-C 4烷基、取代或非取代的苯基或者取代或者非取代的苄基，其中苯基或者苄基被以下取代基团取代：卤素或者C 1-C 3烷基。
优选地，R 1选自选自苄基、3-取代苄基、4-取代苄基或者多取代苄基，所述苄基的取代基为甲基或者卤素；
R 2选自5,6-二乙基-2,3-二氢-1H-茚-2-胺基、N-苯代哌嗪基、N-苯代高哌嗪基、溴苯胺基、2,3-二氢吲哚基或者为2,3-二氢茚基；所述N-苯代哌嗪基选自：苄基取代哌嗪基、甲基苄基取代哌嗪基或者苄基溴取代哌嗪基；N-苯代高哌嗪基选自：苄基取代高哌嗪基、甲基苄基取代高哌嗪基或者苄基溴取代高哌嗪基。
优选地，所述多取代苄基为3，5位卤代苄基、3，4-卤代苄基或者全卤代苄基。
优选地，所述R 1选自苄基、4-甲基苄基、3-氟苄基、4-氟苄基、3，5-二氟苄基、3，4-二氟苄基、全氟代苄基；
R 2选自5,6-二乙基-2,3-二氢-1H-茚-2-胺基、2-溴苯胺基、2,3-二氢吲哚基、2,3-二氢茚基、苄基取代哌嗪基、4-甲基苄基取代哌嗪基、4-溴苄基取代哌嗪基、苄基取代高哌嗪基、4-甲基苄基取代高哌嗪基。
在一些实施例中，所述化合物优选自下列化合物：
Figure PCTCN2022072519-appb-000002
Figure PCTCN2022072519-appb-000003
Figure PCTCN2022072519-appb-000004
本发明所述的化合物具体为以下化合物：
(S)-5-(2-((5,6-二乙基-2,3-二氢-1H-茚-2-基)氨基)-1-羟乙基)-8-((4-氟苄基)氧基)喹啉-2(1H)-酮(I1/LYW2)
(R)-5-(2-((5,6-二乙基-2,3-二氢-1H-茚-2-基)氨基)-1-羟乙基)-8-((4-氟苄基)氧基)喹啉-2(1H)-酮(I2)
(S)-8-((4-氟苄基)氧基)-5-(1-羟基-2-甲氧基乙基)喹啉-2(1H)-酮(I3)
(S)-5-(2-((5,6-二乙基-2,3-二氢-1H-茚-2-基)氨基)-1-羟乙基)-8-((4-甲苄基)氧基)喹啉-2(1H)-酮(I4)
(R)-5-(2-((5,6-二乙基-2,3-二氢-1H-茚-2-基)氨基)-1-羟乙基)-8-((4-甲苄基)氧基)喹啉-2(1H)-酮(I5/LYW3)
(S)-5-(2-((5,6-二乙基-2,3-二氢-1H-茚-2-基)氨基)-1-羟乙基)-8-((3-氟苄基)氧基)喹啉-2(1H)-酮(I6)
(R)-5-(2-((5,6-二乙基-2,3-二氢-1H-茚-2-基)氨基)-1-羟乙基)-8-((3-氟苄基)氧基)喹啉-2(1H)-酮(I7/LYW4)
(R)-5-(2-((5,6-二乙基-2,3-二氢-1H-茚-2-基)氨基)-1-羟乙基)-8-((2-氟苄基)氧基)喹啉-2(1H)-酮(I8)
(S)-5-(2-((5,6-二乙基-2,3-二氢-1H-茚-2-基)氨基)-1-羟乙基)-8-((3,5-二氟苄基)氧基)喹啉-2(1H)-酮(I9)
(S)-5-(2-((5,6-二乙基-2,3-二氢-1H-茚-2-基)氨基)-1-羟乙基)-8-((3,4-二氟苄基)氧基)喹啉-2(1H)-酮(I10)
(S)-5-(2-((5,6-二乙基-2,3-二氢-1H-茚-2-基)氨基)-1-羟乙基)-8-((全氟苄基)氧基)喹啉 -2(1H)-酮(I11)
(R)-8-(苄氧基)-5-(2-(4-丁基哌嗪-1-基)-1-羟乙基)喹啉-2(1H)-酮(I12)
(R)-8-(苄氧基)-5-(2-(4-苄基哌嗪-1-基)-1-羟乙基)喹啉-2(1H)-酮(I13)
(R)-8-(苄氧基)-5-(1-羟基-2-(4-(4-甲基苄基)哌嗪-1-基)乙基)喹啉-2(1H)-酮(I14)
(R)-8-(苄氧基)-5-(2-(4-(4-溴苄基)哌嗪-1-基)-1-羟乙基)喹啉-2(1H)-酮(I15)
(R)-8-(苄氧基)-5-(2-(4-(4-氟苯基)哌嗪-1-基)-1-羟乙基)喹啉-2(1H)-酮(I16)
(R)-8-(苄氧基)-5-(2-(4-苄基-1,4-二氮杂-1-基)-1-羟乙基)喹啉-2(1H)-酮(I17)
(R)-8-(苄氧基)-5-(1-羟基-2-(4-(4-甲基苄基)-1,4-二氮杂-1-基)乙基)喹啉-2(1H)-酮(I18)
(R)-8-(苄氧基)-5-(1-羟基-2-吗啉代乙基)喹啉-2(1H)-酮(I19)
(R)-8-(苄氧基)-5-(1-羟基-2-(哌啶-1-基)乙基)喹啉-2(1H)-酮(I20)
(R)-8-(苄氧基)-5-(1-羟基-2-(吡咯烷基-1-基)乙基)喹啉-2(1H)-酮(I21)
(R)-8-(苄氧基)-5-(1-羟基2-(苯氨基)乙基)-1-羟乙基)喹啉-2(1H)-酮(I22)
(R)-8-(苄氧基)-5-(2-((2-溴苯基)氨基)-1-羟乙基)喹啉-2(1H)-酮(I23)
(R)-8-(苄氧基)-5-(1-羟基-2-(异丁基氨基)乙基)喹啉-2(1H)-酮(I24)
(R)-8-(苄氧基)-5-(2-((2,3-二氢-1H-茚满-2-基)氨基)-1-羟乙基)喹啉-2(1H)-酮(I25)
(R)-8-(苄氧基)-5-(1-羟基-2-(吲哚-1-基)乙基)喹啉-2(1H)-酮(I26)
(R)-8-(苄氧基)-5-(1-羟基-2-((1-(甲磺酰基)哌啶-4-基)氨基)乙基)喹啉-2(1H)-酮(I27)
(R)-8-(苄氧基)-5-(2-(苯并[d]噻唑-5-基氨基)-1-羟乙基)喹啉-2(1H)-酮(I28)
(R)-8-(苄氧基)-5-(2-((1H苯并[d]咪唑-2-基)氨基)-1-羟乙基)喹啉-2(1H)-酮(I29)
(R)-8-(苄氧基)-5-(2-((5,6-二乙基-2,3-二氢-1H-茚-2-基)氨基)-1-氟乙基)喹啉-2(1H)-酮(I’1)
(S)-8-(苄氧基)-5-(2-((5,6-二乙基-2,3-二氢-1H-茚-2-基)氨基)-1-氟乙基)喹啉-2(1H)-酮(I’2)
本发明第二方面提供了上述化合物的制备方法，包括以下步骤：
5-乙酰基-2,8-二羟基喹啉与R 1X反应后溴化得到化合物II，溴化选用的溴化剂可选自溴水、N-溴代琥珀酰亚胺或者四丁基三溴化铵；化合物II通过(R)/(S)-2-甲基-CBS-噁唑硼烷配合硼烷被立体选择性地还原为化合物III，化合物III在碱性条件下分子内环合，后与亲核试剂R 2H反应得到目标化合物I，合成路线如下：
Figure PCTCN2022072519-appb-000005
或化合物I进一步卤化，得到化合物I’：
Figure PCTCN2022072519-appb-000006
优选地，从化合物II制备化合物III的反应中，溶剂选自无水乙腈，无水二氯甲烷，氯仿，无水四氢呋喃，无水N,N′-二甲基甲酰胺、二甲亚砜中的一种或多种；根据其手性要求，分别选择(R)或(S)-CBS类手性催化剂，搭配硼烷进行不对称还原；反应温度为-20℃至25℃。
从化合物III制备化合物IV的反应中：溶剂选自乙腈，二氯甲烷、氯仿、丙酮、四氢呋喃、甲醇、N,N-二甲基甲酰胺、二甲亚砜或二氧六环中的一种或多种；碱选自碳酸钾、碳酸钠、碳酸氢钠、氢氧化钠、氢氧化钾或三乙胺；反应温度为25℃至加热回流；
从化合物IV制备化合物I的反应中：溶剂选自乙腈、N,N-二甲基甲酰胺、二甲亚砜、正丁醇或二乙二醇二甲醚；反应温度为60℃至150℃；
从化合物I制备化合物I’的反应中：溶剂选自乙腈、二氯甲烷、氯仿或四氢呋喃中的一种或多种，在惰性气体保护的条件下与卤化试剂反应，反应温度为-20℃至0℃。
优选地，
作为更优选，所述化合物的制备方法，从化合物II制备化合物III的反应中，溶剂选择无水四氢呋喃，催化剂根据需要选择(R)-2-甲基-CBS-噁唑硼烷或(S)-2-甲基-CBS-噁唑硼烷，反应温度为-20℃至0℃；
从化合物III制备化合物IV的反应中：溶剂选择为丙酮，碱选择为碳酸钾或三乙胺，反应温度为55℃至65℃。
从化合物IV制备化合物I的反应中：溶剂选择为正丁醇，反应温度为110℃至120℃。
这些化合物可按照常规分离技术加以纯化。
优选地，从化合物I制备化合物I’的反应中：溶剂选择为二氯甲烷，在氮气保护下反应，反应温度为-20℃至0℃。
本发明第三方面提供了上述化合物在制备治疗与恶性肿瘤有关疾病药物中的应用。
优选地，所述是与恶性肿瘤有关疾病为SRSF6蛋白过表达介导的各类肿瘤，包括结直肠肿瘤(SRSF6蛋白过表达介导的结直肠肿瘤)。
在本发明的一些实施例中，以茚达特罗及其中间体作为阳性对照，通过体外细胞实验，证明了本发明化合物对RKO、HT-29、SW620等结直肠癌细胞系均具有明显抑制作用。
在本发明的一些实施例中，通过SPR亲和力实验及蛋白热迁移实验，证明了化合物I 1与SRSF6蛋白具有较好的结合作用。
有益效果：本发明的化合物用于靶向治疗SRSF6高表达的结直肠肿瘤和其他肿瘤，为结直肠癌的化学治疗提供潜在药物分子。
附图说明
图1是对本发明代表化合物I 1与SRSF6蛋白片段的结合作用的验证。
具体实施方式
为了进一步阐明本发明，下面给出一系列实施例，这些实施例完全是例证性的，它们仅用来对本发明具体描述，不应当理解为对本发明的限制。
一、化合物合成
实施例1：制备(S)-5-(2-((5,6-二乙基-2,3-二氢-1H-茚-2-基)氨基)-1-羟乙基)-8-((4-氟苄基)氧基)喹啉-2(1H)-酮(I 1)
Figure PCTCN2022072519-appb-000007
1.1中间体II 1的合成
将5-乙酰基-2,8-二羟基喹啉(1g，4.92mmol)和无水碳酸钾(816mg，5.91mmol)加入反应瓶后，加入丙酮(20mL)并升温至回流，在回流条件下滴加4-氟溴苄(727uL，5.91mmol)，充分搅拌后收集滤饼1.3g。
将滤饼(1.3g，4.18mmol)加入反应瓶后，加入无水THF(26mL)和无水甲醇(10mL)并升温至40℃并充分搅拌，再分批次缓慢加入四丁基三溴化铵(2.82g，5.85mmol)，对末端伯碳进行溴化，得到代表性中间体5-(2-溴乙酰基)-8-4-(氟苄基)氧喹啉-2(1H)-酮(化合物Ⅱ 1)。
1H NMR(300MHz,DMSO-d 6)δ11.14(s,1H),8.50(d,J＝10.1Hz,1H),7.88(d,J＝8.6Hz,1H),7.71–7.65(m,2H),7.32(d,J＝8.6Hz,1H),7.25(d,J＝8.9Hz,2H),6.68(d,J＝10.0Hz,1H),5.41(s,2H),4.94(s,2H).MS(ESI)m/z＝390.0[M+H] +(C 18H 13BrFNO 3).
1.2中间体III 1的合成
氮气保护条件下，将化合物II 1(500mg,1.27mmol)加入到100mL双颈反应瓶中，加入无水THF(15mL)和催化量的(S)-2-甲基-CBS-噁唑硼烷(1M,128μL,0.13mmol)，置于-10℃冷阱中充分搅拌。10min后，量取硼烷-四氢呋喃络合物(1M,1.54mL,1.54mmol)，在半小时内缓慢滴入反应体系，在此温度下继续搅拌15min，TLC监测反应完成，用甲醇(5mL)淬灭反应。通过减压浓缩除去溶剂后，向瓶中加入1M盐酸溶液(50mL)，室温搅拌过夜后过滤，收集滤饼，真空干燥后得白色固体III 1 455mg，收率为90.53％。
1H NMR(400MHz,DMSO-d 6)δ10.79(s,1H),8.19(d,J＝10.0Hz,1H),7.69–7.62(m,2H),7.27–7.17(m,4H),6.57(d,J＝9.9Hz,1H),5.97(s,1H),5.28(s,2H),5.26–5.18(m,1H),3.69(dd,J＝10.4,4.8Hz,1H),3.65–3.60(m,1H).MS(ESI)m/z＝392.0[M+H] +(C 18H 15BrFNO 3).
1.3中间体IV 1的合成
将化合物III 1(400mg,1.02mmol)加入到100mL单口反应瓶中，加入重蒸丙酮(40mL) 和无水碳酸钾(211mg,1.53mmol)，加热至回流，充分搅拌。4h后TLC监测反应完成，过滤，用丙酮洗涤滤饼，收集合并滤液。滤液减压浓缩除去溶剂后，加入乙酸乙酯进行重结晶，得到淡黄色固体IV 1 272mg，收率为85.67％。
1H NMR(400MHz,Chloroform-d)δ9.23(s,1H),8.11(d,J＝9.8Hz,1H),7.47–7.39(m,2H),7.16–7.08(m,3H),7.02(d,J＝8.3Hz,1H),6.75(d,J＝9.8Hz,1H),5.16(s,2H),4.26–4.21(m,1H),3.23(dd,J＝5.6,4.0Hz,1H),2.80(dd,J＝5.6,2.6Hz,1H).MS(ESI)m/z＝312.1[M+H] +(C 18H 14FNO 3).
1.4目标产物I 1的合成
将化合物IV 1(250mg,0.80mmol)与5,6-二乙基-2,3-二氢-1H-茚-2-胺(167mg,0.88mmol)加入到单口反应瓶中，加入15mL正丁醇将其溶解后升温至110℃，在此温度下充分搅拌5h，TLC监测反应完成。将反应液浓缩后通过硅胶柱层析纯化，得到目标产物I 1 81mg，收率为20.15％。
1H NMR(400MHz,DMSO-d 6)δ10.81(s,1H),8.28(d,J＝10.0Hz,1H),7.69–7.63(m,2H),7.27–7.18(m,4H),6.98(s,2H),6.58(d,J＝9.9Hz,1H),5.34(d,J＝8.9Hz,1H),3.82(p,J＝7.4Hz,1H),3.12(ddd,J＝15.6,11.7,7.6Hz,2H),3.02–2.82(m,4H),2.57(d,J＝7.5Hz,2H),2.53(d,J＝7.4Hz,2H),1.12(t,J＝7.5Hz,6H). 13C NMR(101MHz,DMSO-d 6)δ161.37,143.93,140.07,138.41,138.36,136.91,132.02,130.67,130.59,129.91,124.64,122.81,119.88,115.69,115.48,112.63,69.48,67.19,58.75,54.18,37.28,25.33,16.10.MS(ESI)m/z＝501.3[M+H] +(C 31H 33FN 2O 3).
实施例2:制备(R)-5-(2-((5,6-二乙基-2,3-二氢-1H-茚-2-基)氨基)-1-羟乙基)-8-((4-氟苄基)氧基)喹啉-2(1H)-酮(I 2)
Figure PCTCN2022072519-appb-000008
(1)中间体III 2的合成
由化合物II制备化合物III时，将反应中的催化剂变更为(R)-2-甲基-CBS-噁唑硼烷即得实施例1中的中间体III 1的对映异构体III 2，步骤如下：
氮气保护条件下，将化合物II 1(500mg,1.27mmol)加入到100mL双颈反应瓶中，加入无水THF(15mL)和催化量的(R)-2-甲基-CBS-噁唑硼烷(1M,128μL,0.13mmol)，置于-10℃冷阱中充分搅拌。10min后，量取硼烷-四氢呋喃络合物(1M,1.54mL,1.54mmol)，在半小时内缓慢滴入反应体系，在此温度下继续搅拌15min，TLC监测反应完成，用甲醇(5mL)淬灭反应。通过减压浓缩除去溶剂后，向瓶中加入1M盐酸溶液(50mL)，室温搅拌过夜后过滤，收集滤饼，真空干燥后得白色固体III 2 461mg，收率为91.73％。
1H NMR(400MHz,DMSO-d 6)δ10.78(s,1H),8.19(d,J＝10.0Hz,1H),7.67–7.63(m,2H),7.24–7.19(m,4H),6.57(d,J＝9.9Hz,1H),5.97(d,J＝4.7Hz,1H),5.29(s,2H),5.23(dt,J＝7.3,4.8Hz,1H),3.69(dd,J＝10.4,4.8Hz,1H),3.62(dd,J＝10.4,7.2Hz,1H).MS(ESI)m/z＝392.0[M+H] +(C 18H 15BrFNO 3).
(2)目标产物I 2的合成
将得到的中间体III 2的合成参照实施例1中步骤1.3的方法，合成中间体IV 2，参照实施例1中步骤1.4的方法，将中间体IV 2(300mg,0.96mmol)和5,6-二乙基-2,3-二氢-1H-茚-2-胺(200mg,1.06mmol)反应，经硅胶柱层析纯化后，得到目标产物I 2 103mg，收率为21.35％。
1H NMR(400MHz,DMSO-d 6)δ10.85(s,1H),8.32(t,J＝11.1Hz,1H),7.65(t,J＝6.9Hz,2H),7.33–7.12(m,4H),6.96(d,J＝14.3Hz,2H),6.59(t,J＝7.8Hz,1H),5.48(s,1H),5.29(s,2H),4.04–3.82(m,2H),3.06(ddd,J＝35.7,20.1,9.8Hz,6H),2.54(d,J＝7.4Hz,3H),1.10(t,J＝6.7Hz,6H). 13C NMR(101MHz,DMSO-d 6)δ161.41,144.09,140.30,137.78,133.26,131.28,130.66,130.58,129.91,124.56,122.96,119.93,117.08,115.69,115.48,112.60,69.46,58.42,36.11,25.31,16.04.MS(ESI)m/z＝501.3[M+H] +(C 31H 33FN 2O 3).
实施例3：制备(S)-8-((4-氟苄基)氧基)-5-(1-羟基-2-甲氧基乙基)喹啉-2(1H)-酮(I 3)
Figure PCTCN2022072519-appb-000009
参照实施例1中步骤1.4的方法，将中间体Ⅳ 1(200mg)和无水甲醇(2mL)反应，经硅胶柱层析纯化后，得到目标产物I 3 128mg，收率为58.03％。
1H NMR(400MHz,DMSO-d 6)δ10.70(s,1H),8.21(d,J＝9.9Hz,1H),7.66(dd,J＝8.5,5.7Hz,2H),7.26–7.19(m,3H),7.06(d,J＝8.3Hz,1H),6.56(d,J＝9.9Hz,1H),5.27(s,2H),4.89(t,J＝5.9Hz,1H),4.65(dd,J＝7.0,4.6Hz,1H),3.65–3.57(m,1H),3.50–3.42(m,1H),3.19(s,3H). 13C NMR(101MHz,DMSO-d 6)δ161.35,144.05,137.22,133.34,133.31,130.69,130.60,129.95,128.99,122.55,121.02,118.22,115.70,115.49,112.46,82.59,69.56,66.08,56.88.MS(ESI)m/z＝344.1[M+H] +(C 19H 18FNO 4).
实施例4：制备(S)-5-(2-((5,6-二乙基-2,3-二氢-1H-茚-2-基)氨基)-1-羟乙基)-8-((4-甲苄基)氧基)喹啉-2(1H)-酮(I 4)
Figure PCTCN2022072519-appb-000010
以4-甲基溴苄替换实施例1中4-氟溴苄，参照实施例1中的方法及反应条件，可得到目标产物I 4。
1H NMR(300MHz,Chloroform-d)δ9.38(s,1H),8.48(s,1H),8.08(d,J＝10.0Hz,1H),7.34–7.28(m,4H),7.21(d,J＝7.7Hz,2H),6.96(d,J＝5.1Hz,2H),6.57(d,J＝9.6Hz,1H),5.62(d,J＝9.5Hz,1H),5.12(d,J＝5.1Hz,2H),3.97–3.83(m,1H),3.29–3.05(m,6H),2.59(q,J＝7.5Hz,4H),2.39(s,3H),1.18(t,J＝7.5Hz,6H). 13C NMR(75MHz, Chloroform-d)δ169.64,161.33,141.06,138.51,136.59,136.17,132.46,129.50,128.90,128.01,124.41,122.64,119.96,111.04,77.26,70.89,66.23,58.97,53.74,36.54,25.45,21.28,15.48.MS(ESI)m/z＝497.3[M+H] +(C 32H 36N 2O 3)
实施例5：制备(R)-5-(2-((5,6-二乙基-2,3-二氢-1H-茚-2-基)氨基)-1-羟乙基)-8-((4-甲苄基)氧基)喹啉-2(1H)-酮(I 5/LYW3)
Figure PCTCN2022072519-appb-000011
以4-甲基溴苄替换实施例1中4-氟溴苄，参照实施例2中的方法及反应条件，可得到目标产物I 5。
1H NMR(300MHz,DMSO-d6)δ8.20(d,J＝10.0Hz,1H),7.45(d,J＝8.0Hz,2H),7.18(d,J＝7.9Hz,4H),6.93(d,J＝2.1Hz,2H),6.54(d,J＝9.9Hz,1H),5.24(s,2H),5.04(t,J＝6.1Hz,1H),3.54-3.49(m,1H),2.98(m,2H),2.73(d,J＝6.4Hz,2H),2.64-2.57(m,2H),2.53(m,4H),2.28(s,3H),1.12(t,J＝7.5Hz,6H). 13C NMR(75MHz,DMSO)δ161.29,143.59,139.73,139.67,139.44,137.57,134.12,133.47,129.78,129.36,128.37,124.63,122.31,119.84,117.26,112.59,70.12,69.41,59.67,56.03,40.26,25.34,21.24,16.15.MS(ESI)m/z＝497.3[M+H] +(C 32H 36N 2O 3).
实施例6：制备(S)-5-(2-((5,6-二乙基-2,3-二氢-1H-茚-2-基)氨基)-1-羟乙基)-8-((3-氟苄基)氧基)喹啉-2(1H)-酮(I 6)
Figure PCTCN2022072519-appb-000012
以3-氟溴苄替换实施例1中4-氟溴苄，参照实施例1中的方法及反应条件，可得到目标产物I 6。
1H NMR(400MHz,DMSO-d 6)δ10.82(s,1H),8.32(s,1H),8.24(d,J＝9.9Hz,1H),7.54(d,J＝8.7Hz,1H),7.42(t,J＝5.6Hz,2H),7.23(s,2H),7.14(ddt,J＝9.0,6.2,2.7Hz,1H),6.97(s,2H),6.59(d,J＝9.9Hz,1H),5.32(s,2H),5.25(dd,J＝9.2,3.6Hz,1H),3.77(p,J＝7.3Hz,1H),3.09(ddd,J＝15.7,10.8,7.5Hz,2H),2.95(td,J＝13.7,12.9,6.2Hz,2H),2.83(dt,J＝16.2,8.0Hz,2H),2.59–2.52(m,4H),1.12(t,J＝7.5Hz,6H). 13C NMR(101MHz,DMSO-d 6)δ165.46,161.43,143.83,139.95,138.66,138.62,136.96,132.48,130.76,130.68,129.87,124.64,124.62,124.14,124.11,122.75,119.91,117.22,115.17,114.98,114.95, 112.54,69.43,67.61,58.88,54.45,37.75,37.68,25.33,16.09.MS(ESI)m/z＝501.3[M+H] +(C 31H 33FN 2O 3).
实施例7：制备(R)-5-(2-((5,6-二乙基-2,3-二氢-1H-茚-2-基)氨基)-1-羟乙基)-8-((3-氟苄基)氧基)喹啉-2(1H)-酮(I 7/LYW4)
Figure PCTCN2022072519-appb-000013
以3-氟溴苄替换实施例1中4-氟溴苄，参照实施例2中的方法及反应条件，可得到目标产物I 7。
1H NMR(400MHz,DMSO-d 6)δ10.77(s,1H),8.21(d,J＝10.0Hz,1H),7.57–7.52(m,1H),7.45–7.39(m,2H),7.19(d,J＝2.0Hz,2H),7.14(ddd,J＝9.0,6.6,2.6Hz,1H),6.93(d,J＝3.5Hz,2H),6.56(d,J＝9.9Hz,1H),5.42(s,1H),5.31(s,2H),5.05(t,J＝6.1Hz,1H),3.52(q,J＝6.6Hz,1H),2.98(ddd,J＝15.5,11.6,6.9Hz,2H),2.77–2.72(m,2H),2.60(t,J＝5.6Hz,1H),2.54(t,J＝7.5Hz,5H),1.12(t,J＝7.5Hz,6H). 13C NMR(101MHz,DMSO-d 6)δ161.46,143.52,139.80,139.75,139.42,137.29,133.84,130.75,130.66,129.77,124.68,124.64,124.12,124.09,122.40,119.86,117.37,115.17,114.95,112.48,69.52,69.43,59.72,56.13,25.34,16.14.MS(ESI)m/z＝501.3[M+H] +(C 31H 33FN 2O 3).
实施例8：制备(R)-5-(2-((5,6-二乙基-2,3-二氢-1H-茚-2-基)氨基)-1-羟乙基)-8-((2-氟苄基)氧基)喹啉-2(1H)-酮(I 8)
Figure PCTCN2022072519-appb-000014
以2-氟溴苄替换实施例1中4-氟溴苄，参照实施例2中的方法及反应条件，可得到目标产物I 8。
1H NMR(300MHz,DMSO-d 6)δ10.62(s,1H),8.42(d,J＝10.0Hz,1H),7.72(t,J＝7.6Hz,1H),7.46–7.34(m,2H),7.26(dd,J＝14.3,7.7Hz,3H),6.91(d,J＝5.8Hz,2H),6.59(d,J＝9.9Hz,1H),5.31(s,2H),5.06(s,1H),4.48(s,1H),3.68–3.49(m,4H),2.86(dp,J＝20.5,6.9Hz,3H),2.54(d,J＝7.9Hz,4H),1.09(t,J＝7.5Hz,6H). 13C NMR(75MHz,DMSO-d 6)δ161.33,143.86,139.67,136.95,131.34,131.29,130.88,130.77,129.80,124.97,124.92,124.71,124.48,123.98,123.79,122.57,121.50,118.68,115.88,115.60,112.59,64.80,57.65,25.30,16.08.MS(ESI)m/z＝501.3[M+H] +(C 31H 33FN 2O 3).
实施例9：制备(S)-5-(2-((5,6-二乙基-2,3-二氢-1H-茚-2-基)氨基)-1-羟乙基)-8-((3，5-二氟苄基)氧基)喹啉-2(1H)-酮(I 9)
Figure PCTCN2022072519-appb-000015
以3，5-二氟溴苄替换实施例1中4-氟溴苄，参照实施例1中的方法及反应条件，可得到目标产物I 9。
1H NMR(400MHz,DMSO-d 6)δ11.01(s,1H),8.34–8.30(m,1H),8.24(d,J＝9.7Hz,1H),7.44(d,J＝6.8Hz,2H),7.23(s,2H),7.17(dt,J＝9.1,2.4Hz,1H),6.97(s,2H),6.59(d,J＝9.9Hz,1H),5.31(s,2H),5.22(s,1H),3.77–3.67(m,1H),3.07(ddd,J＝15.3,11.2,7.3Hz,2H),2.89(p,J＝11.5Hz,2H),2.78(dt,J＝15.2,7.0Hz,2H),2.55(t,J＝7.5Hz,4H),1.12(t,J＝7.5Hz,6H). 13C NMR(101MHz,DMSO-d 6)δ161.52,143.64,139.84,138.85,136.98,129.80,124.64,122.76,119.89,117.28,112.45,111.39,111.14,103.63,68.92,67.92,59.04,54.74,25.33,16.12.MS(ESI)m/z＝519.3[M+H] +(C 31H 32F 2N 2O 3).
实施例10：制备(S)-5-(2-((5,6-二乙基-2,3-二氢-1H-茚-2-基)氨基)-1-羟乙基)-8-((3，4-二氟苄基)氧基)喹啉-2(1H)-酮(I 10)
Figure PCTCN2022072519-appb-000016
以3，4-二氟溴苄替换实施例1中4-氟溴苄，参照实施例1中的方法及反应条件，可得到目标产物I 10。
1H NMR(400MHz,DMSO-d 6)δ10.87(s,1H),8.23(d,J＝10.0Hz,1H),7.85–7.79(m,1H),7.44(q,J＝4.5Hz,2H),7.27–7.19(m,2H),6.95(d,J＝2.0Hz,2H),6.57(d,J＝9.9Hz,1H),5.27(s,2H),5.17(dd,J＝8.1,4.4Hz,1H),3.64(q,J＝7.0Hz,1H),3.04(ddd,J＝15.3,11.3,7.2Hz,2H),2.85(q,J＝7.2,6.2Hz,2H),2.72(ddd,J＝15.7,6.9,3.8Hz,2H),2.55(t,J＝7.5Hz,4H),1.12(t,J＝7.5Hz,6H). 13C NMR(101MHz,DMSO-d 6)δ161.49,143.62,139.71,139.16,139.12,137.09,134.91,133.15,125.20,124.67,124.63,122.62,119.86,117.79,117.62,112.50,68.94,68.40,59.23,55.21,38.64,38.52,25.33,16.13.MS(ESI)m/z＝519.3[M+H] +(C 31H 32F 2N 2O 3).
实施例11：制备(S)-5-(2-((5,6-二乙基-2,3-二氢-1H-茚-2-基)氨基)-1-羟乙基)-8-((全氟苄基)氧基)喹啉-2(1H)-酮(I 11)
Figure PCTCN2022072519-appb-000017
以全氟代溴苄替换实施例1中4-氟溴苄，参照实施例1中的方法及反应条件，可得到目标产物I 11。
1H NMR(400MHz,DMSO-d 6)δ10.84(s,1H),8.21(d,J＝10.0Hz,1H),7.32(d,J＝8.4Hz,1H),7.25(d,J＝8.4Hz,1H),6.95(d,J＝3.8Hz,2H),6.54(d,J＝9.9Hz,1H),5.28(s,2H),5.08(t,J＝6.1Hz,1H),3.54(q,J＝6.7Hz,1H),2.99(ddd,J＝15.4,11.7,7.0Hz,2H),2.76(d,J＝6.2Hz,2H),2.65–2.57(m,2H),2.54(d,J＝7.5Hz,4H),1.12(t,J＝7.5Hz,6H). 13C NMR(101MHz,DMSO-d 6)δ161.54,143.71,139.77,139.45,137.19,134.41,129.52,124.71,124.66,122.57,119.87,117.31,112.21,69.44,59.71,58.48,56.13,25.34,16.16.(ESI)m/z＝573.3[M+H] +(C 31H 29F 5N 2O 3).
实施例12：制备(R)-8-(苄氧基)-5-(2-(4-丁基哌嗪-1-基)-1-羟乙基)喹啉-2(1H)-酮(I 12)
Figure PCTCN2022072519-appb-000018
参照实施例1中步骤1.4的方法，将茚达特罗中间体5-(2R)-2-环氧乙烷基-8-苄氧基-2(1H)-喹啉酮(200mg,0.68mmol)和1-丁基哌嗪(116mg,0.82mmol)反应，经硅胶柱层析纯化后，得到目标产物82mg，收率为27.61％。
1H NMR(300MHz,DMSO-d 6)δ10.64(s,1H),8.18(d,J＝9.9Hz,1H),7.63–7.51(m,2H),7.36(dt,J＝14.4,7.0Hz,3H),7.23–7.11(m,2H),6.54(d,J＝9.9Hz,1H),5.29(s,2H),5.16(d,J＝3.9Hz,1H),2.63–2.46(m,4H),2.44–2.30(m,4H),2.21(t,J＝7.2Hz,4H),1.37(dq,J＝14.6,6.8Hz,2H),1.22(dq,J＝19.9,7.2Hz,2H),0.86(t,J＝7.1Hz,3H).MS(ESI)m/z＝436.3[M+H] +(C 26H 33N 3O 3).
实施例13：制备(R)-8-(苄氧基)-5-(2-(4-苄基哌嗪-1-基)-1-羟乙基)喹啉-2(1H)-酮(I 13)
Figure PCTCN2022072519-appb-000019
参照实施例1中步骤1.4的方法，将茚达特罗中间体5-(2R)-2-环氧乙烷基-8-苄氧基-2(1H)-喹啉酮(200mg,0.68mmol)和1-苄基哌嗪(145mg,0.82mmol)反应，经硅胶柱层析纯化后，得到目标产物105mg，收率为32.79％。
1H NMR(300MHz,DMSO-d6)δ10.58(s,1H),8.12(d,J＝10.0Hz,1H),7.52(d,J＝8.2Hz,2H),7.37-7.06(m,10H),6.49(d,J＝9.9Hz,1H),5.24(s,2H),5.08(m,1H),3.38(s,2H),2.57-2.46(m,2H),2.45-2.08(m,8H). 13C NMR(75MHz,DMSO)δ161.35,143.57,138.71,137.54,137.16,133.91,129.70,129.23,128.78,128.59,128.31,128.25,127.32,122.17,119.91,117.35,112.54,70.21,67.50,66.35,62.54,53.70,53.10.MS(ESI)m/z＝470.2[M+H] +(C 29H 31N 3O 3).
实施例14：制备(R)-8-(苄氧基)-5-(1-羟基-2-(4-(4-甲基苄基)哌嗪-1-基)乙基)喹啉-2(1H)-酮(I 14)
Figure PCTCN2022072519-appb-000020
参照实施例1中步骤1.4的方法，将茚达特罗中间体5-(2R)-2-环氧乙烷基-8-苄氧基-2(1H)-喹啉酮(200mg,0.68mmol)和1-(4-甲基苄基)哌嗪(156mg,0.82mmol)反应，经硅胶柱层析纯化后，得到目标产物125mg，收率为37.91％。
1H NMR(300MHz,DMSO-d6)δ10.58(s,1H),8.12(d,J＝10.0Hz,1H),7.52(d,J＝6.8Hz,2H),7.30(m,3H),7.17-6.99(m,6H),6.49(d,J＝9.9Hz,1H),5.24(s,2H),5.07(m,1H),3.35(s,2H),2.39(m,10H),2.22(s,3H). 13C NMR(75MHz,DMSO)δ161.35,143.57,137.54,137.16,136.30,135.59,133.92,129.70,129.22,129.15,128.78,128.31,128.25,122.16,119.90,117.35,112.52,70.21,67.53,66.36,62.29,53.71,53.07,21.16.MS(ESI)m/z＝484.3[M+H] +(C 30H 33N 3O 3)
实施例15：制备(R)-8-(苄氧基)-5-(2-(4-(4-溴苄基)哌嗪-1-基)-1-羟乙基)喹啉-2(1H)-酮(I 15)
Figure PCTCN2022072519-appb-000021
参照实施例1中步骤1.4的方法，将茚达特罗中间体5-(2R)-2-环氧乙烷基-8-苄氧基-2(1H)-喹啉酮(200mg,0.68mmol)和1-(4-溴苄基)哌嗪(209mg,0.82mmol)反应，经硅胶柱层析纯化后，得到目标产物133mg，收率为35.56％
1H NMR(400MHz,DMSO-d6)δ10.61(s,1H),8.17(d,J＝9.9Hz,1H),7.57(d,J＝7.5Hz,2H),7.50(d,J＝8.2Hz,2H),7.38(t,J＝7.5Hz,2H),7.31(d,J＝7.1Hz,1H),7.24(d,J＝8.2Hz,2H),7.16(q,J＝8.4Hz,2H),6.53(d,J＝9.8Hz,1H),5.29(s,2H),5.15(s,1H),5.11(s,1H),3.40(s,2H),2.60-2.52(m,2H),2.49-2.18(m,8H).MS(ESI)m/z 548.2[M+H] +(C 29H 30BrN 3O 3).
实施例16：制备(R)-8-(苄氧基)-5-(2-(4-(4-氟苯基)哌嗪-1-基)-1-羟乙基)喹啉-2(1H)-酮(I 16)
Figure PCTCN2022072519-appb-000022
参照实施例1中步骤1.4的方法，将茚达特罗中间体5-(2R)-2-环氧乙烷基-8-苄氧基-2(1H)-喹啉酮(200mg,0.68mmol)和1-(4-氟苯基)哌嗪(148mg,0.82mmol)反应，经硅胶柱层析纯化后，得到目标产物221mg，收率为68.45％。
1H NMR(400MHz,DMSO-d 6)δ10.63(s,1H),8.23(d,J＝9.9Hz,1H),7.58(d,J＝7.4Hz,2H),7.38(t,J＝7.4Hz,2H),7.34–7.29(m,1H),7.19(s,2H),7.03(t,J＝8.7Hz,2H),6.92(dd,J＝9.1,4.7Hz,2H),6.56(d,J＝9.9Hz,1H),5.30(s,2H),5.20(dd,J＝8.1,4.3Hz,1H),3.04(t,J＝5.1Hz,4H),2.64(qd,J＝11.2,9.7,5.0Hz,5H),2.48(d,J＝4.1Hz,1H). 13C NMR(101MHz,DMSO-d 6)δ161.37,143.64,137.58,137.17,133.87,129.76,128.80,128.33,128.27,122.22,119.99,117.52,117.44,117.38,115.79,115.58,112.58,70.26,67.70,66.14,53.61,49.42.MS(ESI)m/z 474.3[M+H] +(C 28H 28FN 3O 3).
实施例17：制备(R)-8-(苄氧基)-5-(2-(4-苄基-1,4-二氮杂-1-基)-1-羟乙基)喹啉-2(1H)-酮(I 17)
Figure PCTCN2022072519-appb-000023
参照实施例1中步骤1.4的方法，将茚达特罗中间体5-(2R)-2-环氧乙烷基-8-苄氧基-2(1H)-喹啉酮(200mg,0.68mmol)和1-苄基高哌嗪(130mg,0.82mmol)反应，经硅胶柱层析纯化后，得到目标产物101mg，收率为30.63％。
1H NMR(300MHz,DMSO-d6)δ10.60(s,1H),8.15(d,J＝10.0Hz,1H),7.52(d,J＝8.2Hz,2H),7.36-7.26(m,3H),7.24(m,5H),7.12(d,J＝4.0Hz,2H),6.49(d,J＝9.9Hz,1H),5.24(s,2H),5.02(t,J＝6.2Hz,1H),3.50(s,2H),2.79-2.60(m,6H),2.55-2.48(m,3H),1.59(m,2H). 13C NMR(75MHz,DMSO)δ160.77,142.95,139.35,136.97,136.58,133.22,129.10, 128.34,128.19,127.99,127.71,127.65,126.60,121.55,119.45,116.87,111.98,69.63,67.57,65.09,61.58,54.91,54.57,54.03,53.64,27.21.MS(ESI)m/z＝484.3[M+H] +(C 30H 33N 3O 3).
实施例18：制备(R)-8-(苄氧基)-5-(1-羟基-2-(4-(4-甲基苄基)-1,4-二氮杂-1-基)乙基)喹啉-2(1H)-酮(I 18)
Figure PCTCN2022072519-appb-000024
参照实施例1中步骤1.4的方法，将茚达特罗中间体5-(2R)-2-环氧乙烷基-8-苄氧基-2(1H)-喹啉酮(200mg,0.68mmol)和1-(4-甲基苄基)高哌嗪(167mg,0.82mmol)反应，经硅胶柱层析纯化后，得到目标产物98mg，收率为28.88％。
1H NMR(300MHz,DMSO-d6)δ10.59(s,1H),8.16(d,J＝10.0Hz,1H),7.53(d,J＝6.8Hz,2H),7.31(m,3H),7.16-7.04(m,6H),6.50(d,J＝9.9Hz,1H),5.26(s,2H),5.02(t,J＝6.3Hz,1H),3.46(s,2H),2.76-2.60(m,6H),2.52(m,4H),2.23(s,3H),1.61(m,2H). 13C NMR(75MHz,DMSO)δ161.35,143.53,137.57,137.17,136.79,136.16,133.83,129.69,129.16,128.93,128.78,128.31,128.24,122.14,120.03,117.45,112.56,70.22,68.16,65.68,61.92,55.51,55.07,54.60,54.17,27.81,21.16.MS(ESI)m/z＝498.3[M+H] +(C 31H 35N 3O 3)
实施例19：制备(R)-8-(苄氧基)-5-(1-羟基-2-吗啉代乙基)喹啉-2(1H)-酮(I 19)
Figure PCTCN2022072519-appb-000025
参照实施例1中步骤1.4的方法，将茚达特罗中间体5-(2R)-2-环氧乙烷基-8-苄氧基-2(1H)-喹啉酮(200mg,0.68mmol)和吗啉(72mg,0.82mmol)反应，经硅胶柱层析纯化后，得到目标产物63mg，收率为24.29％。
1H NMR(400MHz,DMSO-d6)δ10.62(s,1H),8.19(d,J＝11.7Hz,1H),7.57(d,J＝7.2Hz,2H),7.42-7.35(m,2H),7.32(d,J＝7.6Hz,1H),7.25-7.13(m,2H),6.55(d,J＝9.9Hz,1H),5.29(s,2H),5.15(s,1H),3.53(s,4H),2.56(m,2H),2.42(m,4H). 13C NMR(101MHz,DMSO)δ161.34,143.59,137.53,137.16,133.84,129.73,128.79,128.34,128.26,122.21,119.95,117.33,112.56,70.24,67.46,66.72,66.69,54.23.MS(ESI)m/z＝381.2[M+H] +(C 22H 24N 2O 4).
实施例20：制备(R)-8-(苄氧基)-5-(1-羟基-2-(哌啶-1-基)乙基)喹啉-2(1H)-酮(I 20)
Figure PCTCN2022072519-appb-000026
参照实施例1中步骤1.4的方法，将茚达特罗中间体5-(2R)-2-环氧乙烷基-8-苄氧基-2(1H)-喹啉酮(200mg,0.68mmol)和哌啶(70mg,0.82mmol)反应，经硅胶柱层析纯化后，得到目标产物87mg，收率为33.71％。
1H NMR(400MHz,DMSO-d6)δ10.63(s,1H),8.19(d,J＝9.9Hz,1H),7.57(d,J＝7.0Hz,2H),7.38(t,J＝7.2Hz,2H),7.31(t,J＝7.3Hz,1H),7.24-7.12(m,2H),6.54(d,J＝9.9Hz,1H),5.29(s,2H),5.16(s,1H),2.56(m,2H),2.42(s,4H),1.53-1.43(m,4H),1.39-1.33(m,2H). 13C NMR(101MHz,DMSO)δ161.35,143.60,137.51,137.16,133.74,129.69,128.79,128.32,128.25,122.17,119.87,117.33,112.56,70.22,67.14,54.82,25.78,24.19.MS(ESI)m/z＝379.2[M+H] +(C 23H 26N 2O 3).
实施例21：制备(R)-8-(苄氧基)-5-(1-羟基-2-(吡咯烷基-1-基)乙基)喹啉-2(1H)-酮(I 21)
Figure PCTCN2022072519-appb-000027
参照实施例1中步骤1.4的方法，将茚达特罗中间体5-(2R)-2-环氧乙烷基-8-苄氧基-2(1H)-喹啉酮(200mg,0.68mmol)和四氢吡咯(58mg,0.82mmol)反应，经硅胶柱层析纯化后，得到目标产物85mg，收率为34.21％。
1H NMR(400MHz,DMSO-d6)δ10.63(s,1H),8.21(d,J＝10.0Hz,1H),7.57(d,J＝8.3Hz,2H),7.37(t,J＝7.3Hz,2H),7.31(t,J＝7.3Hz,1H),7.16(q,J＝8.4Hz,2H),6.54(d,J＝9.9Hz,1H),5.29(s,2H),5.11-5.04(m,1H),2.73(dd,J＝12.5,8.0Hz,1H),2.62(dd,J＝12.5,4.6Hz,1H),2.55(d,J＝6.5Hz,4H),1.65(s,4H). 13C NMR(101MHz,DMSO)δ161.33,143.67,137.43,137.16,133.59,129.78,128.80,128.32,128.25,122.28,120.08,117.37,112.49,70.21,68.83,63.83,54.47,23.57.MS(ESI)m/z＝365.2[M+H] +(C 22H 24N 2O 3).
实施例22：制备(R)-8-(苄氧基)-5-(1-羟基2-(苯氨基)乙基)-1-羟乙基)喹啉-2(1H)-酮(I 22)
Figure PCTCN2022072519-appb-000028
参照实施例1中步骤1.4的方法，将茚达特罗中间体5-(2R)-2-环氧乙烷基-8-苄氧基-2(1H)-喹啉酮(200mg,0.68mmol)和苯胺(76mg,0.82mmol)反应，经硅胶柱层析纯化后，得到目标产物60mg，收率为22.77％。
1H NMR(400MHz,DMSO-d 6)δ10.60(s,1H),8.35(d,J＝10.0Hz,1H),7.57(dt,J＝6.2,1.4Hz,2H),7.38(t,J＝7.3Hz,2H),7.31(t,J＝7.3Hz,1H),7.15(s,2H),6.96(t,J＝7.8Hz,2H),6.62(d,J＝9.9Hz,1H),6.47(d,J＝6.4Hz,2H),6.46(d,J＝1.2Hz,1H),6.05(d,J＝6.1Hz,1H),5.25(s,2H),4.97(t,J＝5.9Hz,1H),4.89(q,J＝6.4Hz,1H),3.68–3.55(m,2H). 13C NMR(101MHz,DMSO-d 6)δ161.33,148.33,143.66,137.19,136.66,130.85,129.79,129.21,128.81,128.35,128.32,122.62,120.09,118.11,116.33,113.17,112.64,70.26,66.05,55.62.MS(ESI)m/z＝387.2[M+H] +(C 24H 22N 2O 3).
实施例23：制备(R)-8-(苄氧基)-5-(2-((2-溴苯基)氨基)-1-羟乙基)喹啉-2(1H)-酮(I 23)
Figure PCTCN2022072519-appb-000029
参照实施例1中步骤1.4的方法，将茚达特罗中间体5-(2R)-2-环氧乙烷基-8-苄氧基-2(1H)-喹啉酮(200mg,0.68mmol)和2-溴苯胺(141mg,0.82mmol)反应，经硅胶柱层析纯化后，得到目标产物85mg，收率为26.79％。
1H NMR(400MHz,DMSO-d6)δ10.68(s,1H,NH),8.35(d,J＝10.0Hz,1H),7.56(d,J＝6.4Hz,2H),7.42(d,J＝7.9Hz,1H),7.39-7.35(d,J＝8.4Hz,1H),7.31(d,J＝6.0Hz,1H),7.16(d,J＝8.4Hz,1H),6.98(m,2H),6.63(d,J＝9.8Hz,1H),6.49(t,J＝7.6Hz,1H),6.25(d,J＝8.2Hz,1H),5.24(s,2H),5.03(s,1H),3.79(m,1H),3.68-3.49(m,1H). 13C NMR(101MHz,DMSO)δ161.29,144.36,143.90,143.87,137.09,136.29,132.61,129.98,129.23,128.97,128.80,128.35,122.90,119.88,118.35,117.70,113.24,112.60,109.68,70.23,65.40,55.31.MS(ESI)m/z＝465.1[M+H] +(C 24H 21BrN 2O 3).
实施例24：制备(R)-8-(苄氧基)-5-(1-羟基-2-(异丁基氨基)乙基)喹啉-2(1H)-酮(I 24)
Figure PCTCN2022072519-appb-000030
参照实施例1中步骤1.4的方法，将茚达特罗中间体5-(2R)-2-环氧乙烷基-8-苄氧基-2(1H)-喹啉酮(200mg,0.68mmol)和异丁胺(123mg,0.82mmol)反应，经硅胶柱层析纯化后，得到目标产物73mg，收率为29.22％。
1H NMR(400MHz,DMSO-d 6)δ8.23(d,J＝10.0Hz,1H),7.57(d,J＝7.1Hz,2H),7.38(t,J＝7.3Hz,2H),7.31(t,J＝7.3Hz,1H),7.21–7.15(m,2H),6.56(d,J＝9.8Hz,1H),5.30(s,2H),5.18–5.13(m,1H),2.76(s,1H),2.74(s,1H),2.45(dd,J＝6.8,1.9Hz,2H),1.72(hept,J＝6.7Hz,1H),0.87(dd,J＝6.7,4.1Hz,6H). 13C NMR(101MHz,DMSO-d 6)δ161.31,143.74,137.16,128.82,128.77,128.27,128.22,119.88,112.57,70.22,68.21,56.89,27.76,20.95.MS(ESI)m/z＝367.2[M+H] +(C 22H 26N 2O 3).
实施例25：制备(R)-8-(苄氧基)-5-(2-(3,4-二氢异喹啉-2(1H)-基)-1-羟乙基)喹啉-2(1H)-酮(I 25)
Figure PCTCN2022072519-appb-000031
参照实施例1中步骤1.4的方法，将茚达特罗中间体5-(2R)-2-环氧乙烷基-8-苄氧基-2(1H)-喹啉酮(200mg,0.68mmol)和(S)-2,3-二氢-1H-茚满-1-胺(109mg,0.82mmol)反应，经硅胶柱层析纯化后，得到目标产物112mg，收率为38.51％。
1H NMR(300MHz,DMSO-d6)δ10.67(s,1H),8.18(d,J＝9.9Hz,1H),7.58(d,J＝7.4Hz,2H),7.39(t,J＝7.3Hz,2H),7.33(d,J＝7.1Hz,1H),7.28(d,J＝7.6Hz,1H),7.23-7.12(m,5H),6.54(d,J＝9.9Hz,1H),5.30(s,2H),5.05(d,J＝5.0Hz,1H),4.19(t,J＝6.6Hz,1H),2.98-2.62(m,5H),2.27(m,1H),1.78-1.66(m,1H).MS(ESI)m/z＝427.2[M+H] +(C 27H 26N 2O 3).
实施例26：制备(R)-8-(苄氧基)-5-(1-羟基-2-(吲哚-1-基)乙基)喹啉-2(1H)-酮(I 26)
Figure PCTCN2022072519-appb-000032
参照实施例1中步骤1.4的方法，将茚达特罗中间体5-(2R)-2-环氧乙烷基-8-苄氧基-2(1H)-喹啉酮(200mg,0.68mmol)和吲哚啉(98mg,0.82mmol)反应，经硅胶柱层析纯化后，得到目标产物103mg，收率为36.62％。
1H NMR(300MHz,DMSO-d6)δ10.64(s,1H),8.04(d,J＝9.9Hz,1H),7.58(d,J＝7.3Hz,2H),7.37(m,3H),7.18(s,2H),6.97(d,J＝6.2Hz,1H),6.89(t,J＝7.6Hz,1H),6.56(d,J＝9.9Hz,1H),6.47(t,J＝7.2Hz,1H),6.33(d,J＝7.6Hz,1H),5.29(s,2H),4.97(t,J＝5.6Hz,1H),4.88(s,1H),3.90(dt,J＝11.4,5.4Hz,2H),3.52(q,J＝9.5,8.9Hz,1H),3.28-3.21(m,1H),2.85(dt,J＝17.1,8.0Hz,2H).MS(ESI)m/z＝413.2[M+H] +(C 26H 24N 2O 3).
实施例27：制备(R)-8-(苄氧基)-5-(1-羟基-2-((1-(甲磺酰基)哌啶-4-基)氨基)乙基)喹啉-2(1H)-酮(I 27)
Figure PCTCN2022072519-appb-000033
参照实施例1中步骤1.4的方法，将茚达特罗中间体5-(2R)-2-环氧乙烷基-8-苄氧基-2(1H)-喹啉酮(200mg,0.68mmol)和1-甲磺酰基-4-氨基哌啶(146mg,0.82mmol)反应，经硅胶柱层析纯化后，得到目标产物52mg，收率为16.17％。
1H NMR(400MHz,DMSO-d 6) 1H NMR(400MHz,DMSO-d 6)δ10.66(s,1H),8.31(s,1H),8.22(d,J＝9.9Hz,1H),7.57(d,J＝6.9Hz,2H),7.38(t,J＝7.3Hz,2H),7.34–7.29(m,1H),7.23–7.16(m,2H),6.57(d,J＝9.9Hz,1H),5.31(s,2H),5.13(dd,J＝7.7,4.7Hz,1H),3.47(dd,J＝11.8,4.6Hz,2H),2.84(s,5H),2.79–2.70(m,3H),1.97–1.89(m,2H),1.46–1.35(m,2H). 13C NMR(101MHz,DMSO-d 6)δ165.37,161.34,143.81,137.19,137.15,132.81,129.82,128.82,128.35,128.26,122.50,119.93,117.27,112.57,70.21,68.42,53.61,53.45,44.44,34.66,30.62,30.41.MS(ESI)m/z＝472.2[M+H] +(C 24H 29N 3O 5S).
实施例28：制备(R)-8-(苄氧基)-5-(2-(苯并[d]噻唑-5-基氨基)-1-羟乙基)喹啉-2(1H)-酮(I 28)
Figure PCTCN2022072519-appb-000034
参照实施例1中步骤1.4的方法，将茚达特罗中间体5-(2R)-2-环氧乙烷基-8-苄氧基-2(1H)-喹啉酮(200mg,0.68mmol)和1,3-苯并噻唑-5-胺(123mg,0.82mmol)反应，经硅胶柱层析纯化后，得到目标产物84mg，收率为27.78％。
1H NMR(400MHz,DMSO-d 6)δ10.60(s,1H),10.10(s,1H),9.12(s,1H),8.43(d,J＝9.9Hz,1H),7.72(d,J＝8.6Hz,1H),7.56(d,J＝7.5Hz,2H),7.37(t,J＝7.5Hz,2H),7.32(s,1H),7.16(d,J＝4.9Hz,2H),6.93(d,J＝8.6Hz,1H),6.87(s,1H),6.64(d,J＝9.6Hz,1H),5.23(s,2H),4.99(t,J＝5.9Hz,1H),3.70(d,J＝10.7Hz,1H),3.66(d,J＝6.9Hz,1H).MS(ESI)m/z＝444.1[M+H] +(C 25H 21N 3O 3S).
实施例29：制备(R)-8-(苄氧基)-5-(2-((1H苯并[d]咪唑-2-基)氨基)-1-羟乙基)喹啉-2(1H)-酮(I 2)
Figure PCTCN2022072519-appb-000035
参照实施例1中步骤1.4的方法，将茚达特罗中间体5-(2R)-2-环氧乙烷基-8-苄氧基-2(1H)-喹啉酮(200mg,0.68mmol)和2-氨基苯并咪唑(109mg,0.82mmol)反应，经硅胶柱层析纯化后，得到目标产物68mg，收率为23.38％。
1H NMR(400MHz,DMSO-d 6)δ10.70(s,1H),8.26(s,1H),7.56(d,J＝7.3Hz,2H),7.38(t,J＝7.3Hz,2H),7.32(d,J＝7.2Hz,1H),7.25–7.16(m,2H),7.15–7.09(m,2H),6.91(dd,J＝6.0,3.2Hz,2H),6.82(d,J＝8.2Hz,1H),6.54(d,J＝9.9Hz,1H),5.34(d,J＝3.6Hz,1H),5.30(s,2H),4.25(dd,J＝15.0,8.1Hz,1H),4.15(dd,J＝14.9,4.1Hz,1H). 13C NMR(101MHz,DMSO-d 6)δ165.06,161.32,155.49,144.05,141.84,137.60,137.11,137.08,134.92,131.72,129.88,128.81,128.33,128.21,122.54,120.86,120.65,120.10,118.82, 117.62,114.87,112.58,111.88,108.50,70.21,68.77,49.41.MS(ESI)m/z＝427.2[M+H] +(C 25H 22N 4O 3).
实施例30：制备(R)-8-(苄氧基)-5-(2-((5,6-二乙基-2,3-二氢-1H-茚-2-基)氨基)-1-氟乙基)喹啉-2(1H)-酮(I’ 1)
Figure PCTCN2022072519-appb-000036
将茚达特罗中间体(R)-8-苄氧基-5-(-2-((5,6-二乙基-2,3-二氢-1H-茚-2-基)氨基)-1-羟乙基)喹啉-2(1H)-酮，即LYW1(100mg)溶于二氯甲烷(5mL)中，氮气置换后降温至-20℃左右，搅拌10min后缓慢滴入氟化试剂DAST(41mg,0.25mmol)，维持温度搅拌至反应完全；反应结束后，加入饱和碳酸氢钠溶液淬灭DAST，二氯甲烷萃取后合并有机层，浓缩后经硅胶柱层析纯化，得到目标化合物60mg，收率约为59.75％。
1H NMR(300MHz,DMSO-d 6)δ8.13(d,J＝9.9Hz,1H),7.63–7.59(m,2H),7.45–7.38(m,3H),7.25(s,1H),7.20(d,J＝8.5Hz,1H),6.99–6.95(m,2H),6.62(d,J＝9.9Hz,1H),5.35(s,2H),3.59(p,J＝6.7,6.2Hz,1H),3.26–3.16(m,1H),3.02(dt,J＝15.5,6.4Hz,3H),2.69–2.62(m,2H),2.59(d,J＝7.7Hz,4H),1.13(d,J＝7.5Hz,6H).MS(ESI)m/z＝485.3[M+H] +(C 31H 33FN 2O 2).
实施例31：制备(S)-8-(苄氧基)-5-(2-((5,6-二乙基-2,3-二氢-1H-茚-2-基)氨基)-1-氟乙基)喹啉-2(1H)-酮(I’ 2)
Figure PCTCN2022072519-appb-000037
将LYW1的对映异构体(S)-8-苄氧基-5-(-2-((5,6-二乙基-2,3-二氢-1H-茚-2-基)氨基)-1-羟乙基)喹啉-2(1H)-酮(100mg)溶于二氯甲烷(5ml)中，氮气置换后降温至-20℃左右，搅拌10min后缓慢滴入氟化试剂DAST(41mg,0.25mmol)，维持温度搅拌至反应完全；反应结束后，加入饱和碳酸氢钠溶液淬灭DAST，二氯甲烷萃取后合并有机层，浓缩后经硅胶柱层析纯化，得到目标化合物63mg，收率约为62.74％。
1H NMR(300MHz,DMSO-d 6)δ8.14(d,J＝9.9Hz,1H),7.62(d,J＝6.9Hz,2H),7.43(t,J＝7.1Hz,3H),7.28(d,J＝8.4Hz,1H),7.22(d,J＝8.4Hz,1H),6.99(d,J＝1.7Hz,2H),6.64(d,J＝9.9Hz,1H),5.37(s,2H),3.68–3.62(m,1H),3.11–2.99(m,3H),2.79–2.65(m,3H),2.61(d,J＝7.5Hz,4H),1.17(d,J＝7.5Hz,6H).MS(ESI)m/z＝485.3[M+H] +(C 31H 33FN 2O 2).
二、化合物I对结直肠癌细胞系的抑制作用
根据茚达特罗的治疗作用，我们筛选了其中间体LYW1为先导化合物，研究了系列化合物I对结直肠癌细胞系的体外抑制作用。发现其对RKO、HT29、SW620均具有较强的抑制作用，具体实验过程及结果如下所示：
Figure PCTCN2022072519-appb-000038
1、化合物I对SW620细胞的抑制作用：
以茚达特罗为阳性对照，配制10、20、30、40μM的浓度梯度，将其对SW620的IC 50固定在20-25μM之间。化合物I以同样浓度梯度配制后进行初筛，具有相较茚达特罗更低IC 50的化合物进行二次筛选，二次筛选时化合物的浓度梯度为1、2、4、8μM。
两轮筛选均作用于结直肠癌细胞系SW620，初始细胞数为每孔5000个，直接测定第48h的细胞存活率，最终确定化合物的IC 50。
细胞存活率＝[(实验组读数-空白组读数)/(对照组读数-空白组读数)]×100％。
表1化合物I对SW620抑制作用
化合物 IC 50(μM) 化合物 IC 50(μM)
茚达特罗 23.05 I 11 6.093
LYW1 3.542 I 13 36.31
I 1(LYW2) 3.121 I 14 22.33
I 2 8.624 I 15 11.02
I 4 2.899 I 17 22.22
I 5(LYW3) 2.975 I 18 19.35
I 6 3.055 I 23 25.61
I 7(LYW4) 2.734 I 25 24.76
I 9 3.154 I 26 20.34
I 10 4.184 / /
2、化合物I对RKO(人结肠腺癌细胞)、HT29(人结肠癌细胞)的抑制作用：
以茚达特罗为阳性对照，将其对RKO、HT29的IC 50固定在10-15μM，其他过程同SW620细胞系。
2、化合物I对RKO(人结肠腺癌细胞)、HT29(人结肠癌细胞)的抑制作用：
以茚达特罗为阳性对照，将其对RKO、HT29的IC 50固定在10-15μM，其他过程同 SW620细胞系。
表2化合物对RKO抑制作用
化合物 IC 50(μM)
茚达特罗 12.79
LYW1 2.033
I 1(LYW2) 1.422
I 2 5.563
I 7(LYW4) 3.107
表3化合物对HT29抑制作用
化合物 IC 50(μM)
茚达特罗 12.71
LYW1 2.425
I 1(LYW2) 1.422
I 2 4.687
I 7(LYW4) 2.663
三、化合物I1与SRSF6蛋白结合作用的研究
SRSF蛋白在mRNA前体的组成性剪接、选择性剪接、mRNA出核以及翻译等基因表达调控过程中发挥着重要作用。SRSF蛋白根据含有RRM结构域的数目不同分为两组，其中SRSF6具有RRM1和RRM2两个结构域。RRM1结构域含有RNP-1和RNP-2保守序列，其能与相关RNA结合；而RRM2结构域中含有进化保守的SWQDLKD七肽序列。在选择性剪接位点的特异性识别中，RRM1和RRM2结构域发挥着不可替代的作用。过表达的SRSF6与细胞黏附因子ZO-1结合诱导了结直肠癌的发生，而茚达特罗被验证可抑制肿瘤的发生发展。因此，我们提取了SRSF6蛋白的RRM1、RRM2结构域片段，通过表面离子共振(surface plasmon resonance，SPR)实验，证实了茚达特罗及其中间体(LYW1)与SRSF6具有显著的结合；接着，我们以LYW1为参照，通过蛋白热迁移实验考察了化合物I 1(LYW2)与SRSF6蛋白的结合能力。
我们以DMSO作为空白组，用56.5μM的SRSF6蛋白分别与LYW1、LYW2按1：10的浓度加入到PCR管中，再避光加入TS染料后，进行热迁移实验。实验结果如下：
表4 SRSF6蛋白热迁移实验结果
# Well Protein Ligand Task ΔTm B ΔTm D
1 A01 SRSF6 DMSO R 0.01 -0.07
2 B01 SRSF6 DMSO R -0.01 0.07
3 C01 SRSF6 LYW1 S -14.11 -13.66
4 D01 SRSF6 LYW1 S -13.12 -12.82
5 E01 SRSF6 LYW2 S -10.35 -10.16
6 F01 SRSF6 LYW2 S -11.58 -10.86
实验结果显示，LYW1、I 1(LYW2)与DMSO相比，两个化合物均使SRSF6蛋白发生了不同程度的负迁移，但LYW1自身具有较强的荧光性，因此，I 1(LYW2)与SRSF6蛋白具有更优异的结合作用(图1)。
综上所述，基于茚达特罗对结直肠癌的抑制作用，我们筛选了先导化合物LYW-1并对结构进行了设计优化，合成了新的系列化合物I。体外研究发现其可显著抑制SRSF6过表达而诱导的结直肠癌细胞的发生发展；体内药物代谢动力学实验结果进一步证明了该系列化合物优于先导化合物LYW-1的体内药物代谢数据，为后续药效、毒理研究提供数据支撑，为以SRSF6为新靶点的小分子抗肿瘤药的成药提供了可能，具有良好的应用前景。

Claims (10)

  1. 一种通式如式(I)所示的化合物：
    Figure PCTCN2022072519-appb-100001
    其中：
    R 1选自取代或者非取代的C 1-C 3直链烷基、取代或者非取代的C 1-C 3烯基、取代或者非取代的C 6-C 10芳基、取代或者非取代的C 6-C 10芳烷基、C 6-C 10卤代芳烷基或C 6-C 10杂芳环基，其中，杂芳基的杂原子各自独立地选自N、O、S；
    R 2选自C 1-C 3烷氧基、取代氨基、C 1-C 8脂肪胺基、饱和或不饱和的取代或者非取代的C 6-C 10芳基、取代或者非取代的C 6-C 10杂芳基、卤代芳香族的碳环胺基或取代或者非取代的5-7元杂环基，其中，杂芳基或者杂环基中的杂原子各自独立地选自N、O、S，卤代的卤原子指氟、氯、溴或者碘；所述取代氨基被以下1-3个取代基分别取代：C 1-C 4烷基、5,6-二乙基茚满基、取代或者非取代苯基、茚满基、吲哚基、甲磺酰基取代的哌啶基、苯并噻唑基、苯并咪唑基；
    X选自羟基或者卤素，所述卤素选自氟、氯、溴和碘；
    手性中心*为S构型或R构型。
  2. 根据权利要求1所述的化合物，其特征在于，R 1选自甲基、烯丙基、取代或者非取代的苄基、取代或者非取代的吡啶基或者三氮唑；所述取代或者非取代的苄基被以下1-3个基团独立取代：卤素或者C 1-C 3烷基；
    R 2选自甲氧基、5,6-二乙基-2,3-二氢-1H-茚-2-胺基、2-氨基茚满基、苯胺基、溴苯胺基、杂芳胺基、C 1-C 4脂肪胺基、吗啉基、哌啶基、吡咯基、取代或者非取代的哌嗪基、取代或者非取代的高哌嗪基、吲哚基、2,3-二氢茚基，其中，取代或者非取代的哌嗪基或者取代或者非取代的高哌嗪基被下列的1-3个独立的取代基所取代：C 1-C 4烷基、取代或非取代的苯基或者取代或者非取代的苄基，其中苯基或者苄基被以下取代基团取代：卤素或者C 1-C 3烷基。
  3. 根据权利要求1所述的化合物，其特征在于，R 1选自选自苄基、3-取代苄基、4-取代苄基或者多取代苄基，所述苄基的取代基为甲基或者卤素；
    R 2选自5,6-二乙基-2,3-二氢-1H-茚-2-胺基、N-苯代哌嗪基、N-苯代高哌嗪基、溴苯胺基、2,3-二氢吲哚基或者为2,3-二氢茚基；所述N-苯代哌嗪基选自：苄基取代哌嗪基、甲基苄基取代哌嗪基或者苄基溴取代哌嗪基；N-苯代高哌嗪基选自：苄基取代高哌嗪基、甲基苄基取代高哌嗪基或者苄基溴取代高哌嗪基。
  4. 根据权利要求1所述的化合物，其特征在于，所述R 1选自苄基、4-甲基苄基、3-氟苄基、4-氟苄基、3，5-二氟苄基、3，4-二氟苄基、全氟代苄基；
    R 2选自5,6-二乙基-2,3-二氢-1H-茚-2-胺基、2-溴苯胺基、2,3-二氢吲哚基、2,3-二氢茚基、苄基取代哌嗪基、4-甲基苄基取代哌嗪基、4-溴苄基取代哌嗪基、苄基取代高哌嗪基、4-甲基苄基取代高哌嗪基。
  5. 根据权利要求1所述的化合物，其特征在于，所述化合物为以下化合物：
    Figure PCTCN2022072519-appb-100002
    Figure PCTCN2022072519-appb-100003
  6. 如权利要求1所述化合物的制备方法，包括以下步骤：
    5-乙酰基-2,8-二羟基喹啉与R 1X反应后溴化得到化合物II，溴化选用的溴化剂选自溴水、N-溴代琥珀酰亚胺或者四丁基三溴化铵；化合物II通过(R)/(S)-2-甲基-CBS-噁唑硼烷配合硼烷被立体选择性地还原为化合物III，化合物III在碱性条件下分子内环合，后与亲核试剂R 2H反应得到目标化合物I：
    Figure PCTCN2022072519-appb-100004
    或化合物I进一步卤化，得到化合物I’：
    Figure PCTCN2022072519-appb-100005
  7. 根据权利要求6所述化合物的制备方法，其特征在于，
    化合物II制备化合物III的反应中：溶剂选自乙腈、二氯甲烷、氯仿、四氢呋喃、N,N′-二甲基甲酰胺、二甲亚砜中的一种或多种；反应温度为-20℃至25℃；
    从化合物III制备化合物IV的反应中：溶剂选自乙腈，二氯甲烷、氯仿、丙酮、四氢呋喃、甲醇、N,N-二甲基甲酰胺、二甲亚砜或二氧六环中的一种或多种；碱选自碳酸钾、碳酸钠、碳酸氢钠、氢氧化钠、氢氧化钾或三乙胺；反应温度为25℃至加热回流；
    从化合物IV制备化合物I的反应中：溶剂选自乙腈、N,N-二甲基甲酰胺、二甲亚砜、正丁醇或二乙二醇二甲醚；反应温度为60℃至150℃；
    从化合物I制备化合物I’的反应中：溶剂选自乙腈、二氯甲烷、氯仿或四氢呋喃中的一种或多种，在惰性气体保护的条件下与卤化试剂反应，反应温度为-20℃至0℃。
  8. 根据权利要求7所述化合物的制备方法，其特征在于：
    从化合物II制备化合物III的反应中：溶剂选择无水四氢呋喃，反应温度为-20℃至0℃；
    从化合物III制备化合物IV的反应中：溶剂选择为丙酮，碱选择为碳酸钾或三乙胺，反应温度为55℃至65℃；
    从化合物IV制备化合物I的反应中：溶剂选择为正丁醇，反应温度为110℃至120℃。
    从化合物I制备化合物I’的反应中：溶剂选择为二氯甲烷，在氮气保护下反应，反应温度为-20℃至0℃
  9. 如权利要求1-5任一项所述的化合物在制备治疗与恶性肿瘤有关疾病药物中的应用。
  10. 如权利要求9所述的应用，其特征在于，所述是与恶性肿瘤有关疾病为SRSF6蛋白过表达介导的肿瘤，包括结直肠肿瘤。
PCT/CN2022/072519 2021-11-03 2022-01-18 靶向srsf6蛋白的小分子化合物及其制备方法和用途 WO2023077678A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111293452.X 2021-11-03
CN202111293452.XA CN115677577A (zh) 2021-11-03 2021-11-03 靶向srsf6蛋白的小分子化合物及其制备方法和用途

Publications (1)

Publication Number Publication Date
WO2023077678A1 true WO2023077678A1 (zh) 2023-05-11

Family

ID=85059725

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/072519 WO2023077678A1 (zh) 2021-11-03 2022-01-18 靶向srsf6蛋白的小分子化合物及其制备方法和用途

Country Status (2)

Country Link
CN (1) CN115677577A (zh)
WO (1) WO2023077678A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115521254B (zh) * 2022-09-27 2024-05-31 中国药科大学 一种茚达特罗衍生物及其制备方法和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1353692A (zh) * 1999-06-04 2002-06-12 诺瓦提斯公司 β2－肾上腺受体激动剂
CN1798559A (zh) * 2003-04-04 2006-07-05 诺瓦提斯公司 用于治疗气管疾病的喹啉－2－酮衍生物
CN107021921A (zh) * 2016-02-02 2017-08-08 常州爱诺新睿医药技术有限公司 一种茚达特罗中间体的盐及其制备方法
CN107582550A (zh) * 2017-09-12 2018-01-16 浙江大学 茚达特罗在治疗结直肠癌中的应用
CN110013481A (zh) * 2019-04-30 2019-07-16 暨南大学 马来酸茚达特罗在制备抗肿瘤药物中的应用
WO2021003161A1 (en) * 2019-07-01 2021-01-07 Curasen Therapeutics, Inc. Beta adrenergic agonist and methods of using the same

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1353692A (zh) * 1999-06-04 2002-06-12 诺瓦提斯公司 β2－肾上腺受体激动剂
CN1798559A (zh) * 2003-04-04 2006-07-05 诺瓦提斯公司 用于治疗气管疾病的喹啉－2－酮衍生物
CN107021921A (zh) * 2016-02-02 2017-08-08 常州爱诺新睿医药技术有限公司 一种茚达特罗中间体的盐及其制备方法
CN107582550A (zh) * 2017-09-12 2018-01-16 浙江大学 茚达特罗在治疗结直肠癌中的应用
CN110013481A (zh) * 2019-04-30 2019-07-16 暨南大学 马来酸茚达特罗在制备抗肿瘤药物中的应用
WO2021003161A1 (en) * 2019-07-01 2021-01-07 Curasen Therapeutics, Inc. Beta adrenergic agonist and methods of using the same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Master's Thesis", 1 May 2017, TIANJIN MEDICAL UNIVERSITY, CN, article CHU, XIAOQIN: "Study on Synthesis Process of Indacaterol Maleate", pages: 1 - 80, XP009545533 *
BAUR, FRANCOIS ET AL.: "The Identification of Indacaterol as an Ultralong-Acting Inhaled β2-Adrenoceptor Agonist.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 53, no. 9, 19 April 2010 (2010-04-19), pages 3675 - 3684, XP055121338, ISSN: 1520-4804, DOI: 10.1021/jm100068m *
DATABASE Registry 11 June 2008 (2008-06-11), ANONYMOUS : "2(1H)-Quinolinone, 5-[(1 S)-2-[(2,3-dihydro-1 H-inden-2-yl)amino]- 1- hydroxyethyl]-8-(ph enylmethoxy)-", XP093064765, retrieved from CAS Database accession no. 1027305-45-8 *

Also Published As

Publication number Publication date
CN115677577A (zh) 2023-02-03

Similar Documents

Publication Publication Date Title
JP3330706B2 (ja) キナゾリン誘導体、その製法及びこれを含有する抗癌作用を有する医薬組成物
KR910009199B1 (ko) 신규 헤테로고리 화합물 및 그를 유효 성분으로 함유하는 항암제 강화제
AU2013371146C1 (en) 2,3-dihydro-isoindole-1-on derivative as BTK kinase suppressant, and pharmaceutical composition including same
TW200403224A (en) Novel compounds
AU2009237938A1 (en) Quinoline derivatives as AXL kinase inhibitors
WO2015007249A1 (zh) N-烷基色胺酮衍生物及其制备方法和应用
EA020330B1 (ru) Хиназолиновые соединения
WO2016169504A1 (zh) 稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用
WO2020253711A1 (zh) 一种吡咯并吡啶酮类化合物、其制备方法、其组合物和用途
WO2023077678A1 (zh) 靶向srsf6蛋白的小分子化合物及其制备方法和用途
CN106674136B (zh) 嘧啶类抗肿瘤化合物及其制备方法
WO2019154177A1 (zh) 嘧啶类化合物、其制备方法及其医药用途
WO2020043023A1 (zh) 一种含氟取代苯并咪唑衍生物及应用
CN104341386A (zh) 一类芳基杂环小分子化合物、其衍生物及其制备方法和用途
CN108329274A (zh) 布鲁顿酪氨酸激酶抑制剂
US8258168B2 (en) 2H or 3H-benzo[E]indazol-1-YL carbamate derivatives, the preparation and therapeutic use thereof
Wu et al. Synthesis and Biological Evaluation of [1, 2, 4] Triazolo [3, 4‐a] phthalazine and Tetrazolo [5, 1‐a] phthalazine Derivatives Bearing Substituted Benzylpiperazine Moieties as Positive Inotropic Agents
Marshall et al. Exploring the isoform selectivity of TGX-221 related pyrido [1, 2-a] pyrimidinone-based Class IA PI 3-kinase inhibitors: synthesis, biological evaluation and molecular modelling
WO2023130539A1 (zh) 一种三唑并嘧啶醇类化合物及其制备方法和应用
WO2019223777A1 (zh) 一种含有芳胺基取代的吡咯并嘧啶类化合物、制备方法及其应用
WO2021241611A1 (ja) 複素環化合物の製造方法
CN108947904B (zh) 一种含有七元内酰胺环的化合物及其应用
WO2015043487A1 (zh) 喹唑啉类化合物及其制备方法与应用
CN116425721B (zh) 作为mat2a抑制剂的双环类化合物
CN112574094B (zh) 吲哚酮衍生物及其制药用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22888719

Country of ref document: EP

Kind code of ref document: A1